-
Something wrong with this record ?
The value of 18F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy
M. Myslivecek, C. Neoral, R. Vrba, K. Vomackova, J. Cincibuch, R. Formanek, P. Koranda, J. Zapletalova
Language English Country Czech Republic
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
- MeSH
- Adenocarcinoma mortality MeSH
- Chemoradiotherapy, Adjuvant MeSH
- Adult MeSH
- Esophagectomy MeSH
- Fluorodeoxyglucose F18 diagnostic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Esophageal Neoplasms mortality therapy MeSH
- Neoadjuvant Therapy MeSH
- Radiopharmaceuticals diagnostic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Carcinoma, Squamous Cell mortality therapy MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
AIM: To evaluate the ability of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) to predict histopathological response and overall survival (OS) after preoperative neoadjuvant chemoradiotherapy (CRT) in patients with the esophageal carcinoma. METHODS: 73 patients with locally advanced esophageal carcinoma were included in the study. All were treated with CRT and 34 subsequently underwent surgical resection of the esophagus. (18)F-FDG PET/CT was carried out prior to (PET/ CT1) and 6 weeks after (PET/CT2) completion of the CRT. RESULTS: PET/CT2-determined complete metabolic response (CMR) was achieved in 6 (17.6%) out of 34 operated patients, the metabolic response was incomplete (NCMR) in 28 (82.4%) patients. A histopathological complete response (CR) to CRT was discovered in 7 patients (20.6%). The median OS in operated patients was 17.1 months, 95% CI:12.9-23.3 months. In a group of 39 non-operated patients, CMR after neoadjuvant CRT was achieved in 12 patients (30.8%), while NCMR was found in 28 (82.4%). The median OS was 13.5 months in this group, 95% CI: 4.4-22.7 months. CONCLUSION: No statistically significant correlation was found between the (18)F-FDG metabolic response after the neoadjuvant CRT and histopathological response. Presently, the contribution of (18)F-FDG PET/CT as a marker of the potential result of CRT cannot be considered definite. Another study with a larger sample of patients and standardized algorithms for the examining protocols would be necessary for reaching definitive conclusions.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12039738
- 003
- CZ-PrNML
- 005
- 20140324112748.0
- 007
- ta
- 008
- 121217s2012 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2011.048 $2 doi
- 035 __
- $a (PubMed)22660205
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Mysliveček, Miroslav, $d 1946- $7 jn20000401824 $u Department of Nuclear Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
- 245 14
- $a The value of 18F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy / $c M. Myslivecek, C. Neoral, R. Vrba, K. Vomackova, J. Cincibuch, R. Formanek, P. Koranda, J. Zapletalova
- 520 9
- $a AIM: To evaluate the ability of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) to predict histopathological response and overall survival (OS) after preoperative neoadjuvant chemoradiotherapy (CRT) in patients with the esophageal carcinoma. METHODS: 73 patients with locally advanced esophageal carcinoma were included in the study. All were treated with CRT and 34 subsequently underwent surgical resection of the esophagus. (18)F-FDG PET/CT was carried out prior to (PET/ CT1) and 6 weeks after (PET/CT2) completion of the CRT. RESULTS: PET/CT2-determined complete metabolic response (CMR) was achieved in 6 (17.6%) out of 34 operated patients, the metabolic response was incomplete (NCMR) in 28 (82.4%) patients. A histopathological complete response (CR) to CRT was discovered in 7 patients (20.6%). The median OS in operated patients was 17.1 months, 95% CI:12.9-23.3 months. In a group of 39 non-operated patients, CMR after neoadjuvant CRT was achieved in 12 patients (30.8%), while NCMR was found in 28 (82.4%). The median OS was 13.5 months in this group, 95% CI: 4.4-22.7 months. CONCLUSION: No statistically significant correlation was found between the (18)F-FDG metabolic response after the neoadjuvant CRT and histopathological response. Presently, the contribution of (18)F-FDG PET/CT as a marker of the potential result of CRT cannot be considered definite. Another study with a larger sample of patients and standardized algorithms for the examining protocols would be necessary for reaching definitive conclusions.
- 650 _2
- $a adenokarcinom $x mortalita $x radioizotopová diagnostika $7 D000230
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a spinocelulární karcinom $x mortalita $x radioizotopová diagnostika $x terapie $7 D002294
- 650 _2
- $a adjuvantní chemoradioterapie $7 D059186
- 650 _2
- $a nádory jícnu $x mortalita $x radioizotopová diagnostika $x terapie $7 D004938
- 650 _2
- $a ezofagektomie $7 D016629
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluorodeoxyglukosa F18 $x diagnostické užití $7 D019788
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a radiofarmaka $x diagnostické užití $7 D019275
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Neoral, Čestmír, $d 1952- $7 xx0000421 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
- 700 1_
- $a Vrba, Radek $7 xx0062746 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
- 700 1_
- $a Vomáčková, Katherine $7 xx0142837 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
- 700 1_
- $a Cincibuch, Jan $7 xx0135583 $u Department of Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
- 700 1_
- $a Formánek, Radim $7 xx0104246 $u Department of Nuclear Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Koranda, Pavel, $d 1957- $7 ola2003193656 $u Department of Nuclear Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Zapletalová, Jana $7 xx0111614 $u Department of Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 156, č. 2 (2012), s. 171-179
- 856 41
- $u http://biomed.papers.upol.cz/magno/bio/2012/mn2.php $y domovská stránka časopisu - plný text volně přístupný = fulltext
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20121217 $b ABA008
- 991 __
- $a 20140324112821 $b ABA008
- 999 __
- $a ok $b bmc $g 963290 $s 797326
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 156 $c 2 $d 171-179 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK138 $a Pubmed-20121217
